Komori
Semiannual Report4553TOWA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Semiannual Report — FY2026 H1

What TOWA PHARMACEUTICAL CO.,LTD. reported for the period from 2026-04-01 to 2027-03-31.

How much it says
68Detailed
What moved here
36named for the first time
Its own wording
40terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the current interim consolidated accounting period, revenue and operating profit increased, while ordinary profit and interim net income attributable to owners of the parent decreased, mainly due to the recognition of a ¥2,355 million valuation loss on derivatives. The filing also describes the planned acquisition of all shares in Tanabe Pharma Factory, making it a wholly owned subsidiary (scheduled date: end of December 2026).

Komori's summary of this document, not the document's own words.
68Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
Magnitude of change
68
Detailed
Strategic shift
90
Very detailed
Capital movement
75
Very detailed
Disclosure gaps
50
Typical
Future commitments
68
Detailed
Risk changes
55
Typical
Finance and capital policy
100
Very detailed
Specificity of disclosure
53
Typical
Product portfolio
55
Typical
Technology position
50
Typical
Confidence in strategic bets
R&D spend93億円Money spent making new things.
Cash left over33億円Cash from the business, less what went into equipment.
Spent on equipment71億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
TOWA PHARMACEUTICAL CO.,LTD. — FY2026 H1 | Komori